© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org.
Brief Report |
Participation of Asian-American Women in Cancer Treatment Research: A Pilot Study
Affiliations of authors: Vietnamese Community Health Promotion Project, Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA (TTN, TN); Kaiser Permanente Northern California, Division of Research, Oakland, CA (CPS); Department of Adolescent Medicine, University of California, San Francisco, CA (YM); Chinatown Public Health Center, San Francisco Department of Public Health, San Francisco, CA (L-CF)
Correspondence to: Tung T. Nguyen, MD, Box 0320, University of California, San Francisco, San Francisco, CA 94143 (e-mail: tung{at}itsa.ucsf.edu).
 |
ABSTRACT |
|---|
 TopNotes Abstract References |
|---|
Few Asian-American women participate in cancer treatment trials. In a pilot study to assess barriers to participation, we mailed surveys to 132 oncologists and interviewed 19 Asian-American women with cancer from Northern California. Forty-four oncologists responded. They reported as barriers language problems, lack of culturally relevant cancer information, and complex protocols. Most stated that they informed Asian-American women about treatment trials. Only four women interviewed knew about trials. Other patient-identified barriers were fear of side effects, language problems, competing needs, and fear of experimentation. Family decision making was a barrier for both oncologists and patients. Compared to non-Asian oncologists, more Asian oncologists have referred Asian-American women to industry trials and identified barriers similar to patients' reports. Our findings indicate that Asian-American women need to be informed about cancer treatment trials, linguistic barriers should be addressed, and future research should evaluate cultural barriers such as family decision making.
Few Asian-American women participate in cancer treatment trials, but little is known about the barriers involved (1–3). We conducted a pilot study with oncologists and Asian-American women to describe these barriers. Because trial participation is a complex process, we used the Pathways Model, a comprehensive framework that postulates that health-related behaviors require patients to negotiate a Community Pathway and providers a Medical Pathway, each with barriers and facilitating factors (4–5). The pathways interact through language and cultural concordance, system capacity, and patient education. We hypothesized that patients and physicians perceived different types of barriers, that both would identify language discordance as a barrier, and that Asian oncologists were more likely than non-Asians to identify barriers consistent with the patients' reports.
In 2003, using lists from the American Medical Association, the American Society of Clinical Oncologists, and hospitals (excluding Kaiser Permanente), we mailed anonymous surveys to all 132 medical oncologists in three Northern California counties. Items included sociodemographics, practice characteristics, proportion of Asian-American women with whom trials were discussed, and proportions of Asian-American women who were referred to and enrolled in trials. Using a 5-point scale, oncologists reported research attitudes, rated physician barriers, and assessed 23 barriers relevant to these women. Statistical analyses were performed using SAS (SAS Institute, Cary, NC).
Bilingual researchers conducted individual, face-to-face, semistructured interviews in Cantonese, English, or Vietnamese with 10 Chinese and 9 Vietnamese women with cancer from Northern California. The interviews were audiotaped, transcribed, and translated into English. Participants were asked whether they had heard of trials, whether trials were ever discussed, and whether they participated. Using open-ended questions followed by probes, the interviewer assessed research perceptions, attitudes, and barriers. Participants also rated 34 factors for their importance. Using standard techniques (6–7), two researchers independently coded transcripts using an iterative process and resolved differences by consensus.
Forty-four oncologists responded (response rate = 33.3%). Most had information about trials and had positive attitudes. The major Medical Pathway barriers included lack of staff, lack of time, effort to learn about trials, and eligibility criteria. Many (62.9%) had discussed trials with at least 5% of Asian-American women in the preceding 6 months.
Most Asian oncologists spoke an Asian language. Asian and non-Asian oncologists reported similar attitudes, physician barriers, and NCI trials behavior. More Asian than non-Asian oncologists had referred (75.0% vs. 9.5%, P
.001) and enrolled (40.0% vs. 9.5%, P<.05) Asian-American women in industry trials.
Few oncologists thought that Asian-Americans were reluctant to participate or that physicians were not informing them about trials (Table 1). The oncologists reported that the main barriers for Asian-American women were pathways interactions such as researcher–participant language discordance, lack of culturally relevant cancer information, and complex protocols. Family decision making was the main Community Pathway barrier.
|
Significantly more Asian than non-Asian oncologists chose as patient barriers lack of culturally relevant cancer information (64.3% vs. 32.1%) and fear of experimentation (50.0% vs. 20.7%) (P<.05). Although not statistically significant, more Asian oncologists chose lack of knowledge about research and family decision making as Community Pathway barriers.
All 19 patients were foreign born with ages ranging from 33 to 71 years. Most had limited English proficiency. Few had oncologists who spoke Asian languages. Only four had heard of treatment trials (Table 2). Fear of side effects was the main barrier to participation, followed by language problems, competing needs, and fear of experimentation or distrust. Family reluctance was also a prominent barrier. Many would consider participation if their physicians recommended it in a respectful manner.
|
Consistent with a prior study (3), oncologists and patients agreed that language was a barrier to trial participation for Asian-American women. Language discordance affects physician–patient communication among Asian-Americans (8–9) and research participation in other populations (10). In this study, Asian oncologists were more likely to speak an Asian language and to have enrolled Asian-American women in industry trials. This indicates that language and possibly cultural concordance can lead to more participation. However, many Asian-American women with cancer received care from non-Asian oncologists. To facilitate trial participation, these patients may need language and cultural support through interpreters or patient navigators.
An important factor identified by both oncologists and patients but not in the literature was the family decision-making process, which is important in other Asian-American health behaviors (11). Even non-Asian oncologists identified this barrier, indicating that it is prevalent enough to be perceived by those from a different culture. This cultural factor deserves further investigation, but our finding indicates that family members should be involved in the discussion about trial participation.
Oncologists and patients disagreed on other barriers. Most oncologists reported trial discussion with these women, but similar to findings in other groups, patients reported that they were not informed (12,13–14). Oncologists and patients also differed regarding willingness to participate. The women would participate only under dire circumstances. Their reluctance is more marked than that reported in other groups (15–16). This may be a result of lack of knowledge about cancer and the research process, as people who knew more were more willing to participate (16). Distrust, a barrier among African Americans (12,17), was reported by some Asian-American women but not by oncologists.
Reflecting the views of the patients, more Asian than non-Asian oncologists identified as barriers lack of culturally relevant cancer information, fear of experimentation, and family decision making. As a result of having a shared background, Asian oncologists may have insight about barriers for Asian-American patients. Including ethnically concordant physicians in studies may lead to culturally appropriate interventions to increase participation (17–18).
Because of major limitations, the results of this pilot study are preliminary. The sampling frame and low response rate of the survey and the small number of foreign-born women interviewed limit the generalizability. Future studies could include physician–patient pairs to evaluate their interaction, and qualitative studies could evaluate cultural factors such as family decision making. Nonetheless, our findings indicate that more oncologists should discuss treatment trials with Asian-American women and that studies of linguistically and culturally appropriate recruitment methods are needed.
|
NOTES |
|---|
This study was funded by an Administrative Supplement to the Cancer Research Network, a consortium of non-profit integrated health care delivery systems and the National Cancer Institute (Grant U19/CA 79689). Dr. Nguyen was supported by the Asian-American Network for Cancer Awareness Research and Training (NCI Grant U01/CA 86322) and an American Cancer Society Cancer Control Career Development Award. We would like to thank Judy Dang, Leslie Lin, and Judith Luce, MD, for their help and Stephen J. McPhee, MD, and Edward Wagner, MD, MPH, for their support.
|
REFERENCES |
|---|
|
TopNotesAbstractReferences |
|---|
(1) Alexander GA, Chu KC, Ho RC. Representation of Asian-Americans in clinical cancer trials. Ann Epidemiol 2000;10:S61–7.[CrossRef][ISI][Medline]
(2) Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720–61.
(3) Capacity-Building Initiative for Asian-American and Pacific Islanders to Participate in Clinical Research Studies: Summary Report of Needs Assessment. Oakland, CA: Association of Asian Pacific Community Health Organizations, 2000.
(4) Hiatt RA, Pasick R, Perez-Stable E, McPhee S, Englestad L, Lee M. Pathways to early cancer detection in the multiethnic population of the San Francisco Bay area. Health Educ Q 1996;23:S10–S27.
(5) Green L, Kreuter MW. Health Promotion Planning: An Educational and Environmental Approach (2nd ed.). Mountain View, CA: Mayfield, 1991.
(6) Strauss A, Corbin J. Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory. Newbury Park, CA: Sage Publications, 1998.
(7) Pope C, Ziebland S, Mays N. Analysing qualitative data. Br Med J 2000;320:114–6.
(8) Weech-Maldonado R, Elliott MN, Morales LS, Spritzer K, Marshall GN, Hays RD. Health plan effects on patient assessments of Medicaid managed care among racial/ ethnic minorities. J Gen Intern Med 2004;19:136–45.[CrossRef][ISI][Medline]
(9) Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care. J Gen Intern Med 2003;18:44–52.[CrossRef][ISI][Medline]
(10) Napoles-Springer A, Grumbach K, Alexander M, et al. Clinical Research with Older African Americans and Latinos. Res Aging 2000;22:668–91.
(11) Kagawa-Singer M, Blackhall LJ. Negotiating cross-cultural issues at the end of life: "You got to go where he lives." JAMA 2001;286:2993–3001.
(12) Roberson NL. Clinical trial participation. Viewpoints from racial/ethnic groups. Cancer 1994;74:2687–91.[CrossRef][ISI][Medline]
(13) Finn R. Surveys identify barriers to participation in clinical trials. J Natl Cancer Inst 2000;92:1556–8.
(14) Lynch GF, Gorelick PB, Raman R, Leurgans S. A pilot survey of African-American physician perceptions about clinical trials. J Natl Med Assoc 2001;93:8S–13S.[Medline]
(15) Advani AS, Atkeson B, Brown CL, Peterson BL, Fish L, Johnson JL, et al. Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. Cancer 2003;97:1499–506.[CrossRef][ISI][Medline]
(16) Ellis PM, Butow PN, Tattersall MH, Dunn SM, Houssami N. Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 2001;19:3554–61.
(17) Pinto HA, McCaskill-Stevens W, Wolfe P, Marcus AC. Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative. Ann Epidemiol 2000;10: S78–84.[CrossRef][ISI][Medline]
(18) Sheppard VB, Cox LS, Kanamori MJ, Canar J, Rodriguez Y, Goodman M, et al. Brief report: if you build it, they will come: methods for recruiting Latinos into cancer research. J Gen Intern Med 2005;20:444–7.[CrossRef][ISI][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.-R. Han, K. B. Kim, and M. T. Kim Evaluation of the training of Korean community health workers for chronic disease management Health Educ. Res., August 1, 2007; 22(4): 513 - 521. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||